NO20012916L - Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser - Google Patents

Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser

Info

Publication number
NO20012916L
NO20012916L NO20012916A NO20012916A NO20012916L NO 20012916 L NO20012916 L NO 20012916L NO 20012916 A NO20012916 A NO 20012916A NO 20012916 A NO20012916 A NO 20012916A NO 20012916 L NO20012916 L NO 20012916L
Authority
NO
Norway
Prior art keywords
compositions
methods
anorectal disorders
treating anorectal
treating
Prior art date
Application number
NO20012916A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012916D0 (no
Inventor
Thomas P Parks
Vivien Mak
Jung-Chung Lee
Charles Lee
Original Assignee
Cellegy Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27381146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20012916(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellegy Pharma Inc filed Critical Cellegy Pharma Inc
Publication of NO20012916D0 publication Critical patent/NO20012916D0/no
Publication of NO20012916L publication Critical patent/NO20012916L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20012916A 1998-12-14 2001-06-13 Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser NO20012916L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11232598P 1998-12-14 1998-12-14
US13991699P 1999-06-17 1999-06-17
US15531899P 1999-09-21 1999-09-21
PCT/US1999/029459 WO2000035434A2 (en) 1998-12-14 1999-12-13 Compositions and methods for the treatment of anorectal disorders

Publications (2)

Publication Number Publication Date
NO20012916D0 NO20012916D0 (no) 2001-06-13
NO20012916L true NO20012916L (no) 2001-08-14

Family

ID=27381146

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012916A NO20012916L (no) 1998-12-14 2001-06-13 Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser

Country Status (14)

Country Link
US (2) US6395736B1 (enExample)
EP (1) EP1143956A3 (enExample)
JP (1) JP2002542147A (enExample)
KR (1) KR20010093828A (enExample)
CN (2) CN1526448A (enExample)
AU (1) AU764921B2 (enExample)
BR (1) BR9916162A (enExample)
CA (1) CA2354543A1 (enExample)
CZ (1) CZ20012113A3 (enExample)
HU (1) HUP0104676A3 (enExample)
IL (1) IL143726A0 (enExample)
NO (1) NO20012916L (enExample)
PL (1) PL348817A1 (enExample)
WO (1) WO2000035434A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
GB9924636D0 (en) * 1999-10-18 1999-12-22 Norgine Bv Laxative preparation
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
MXPA03000931A (es) * 2000-07-31 2004-08-12 Cellegy Pharma Inc Composiciones y metodos para el tratamientos de trastornos anorectales.
GB0020588D0 (en) * 2000-08-21 2000-10-11 Pfizer Ltd Treatment of wounds
AU2000270300A1 (en) * 2000-09-13 2002-03-26 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
EP2351765A3 (en) * 2001-07-10 2012-02-22 Lakewood-Amedex, Inc Oligonucleotide-containing pharmacological compositions and their use
WO2003022239A2 (en) * 2001-09-07 2003-03-20 Western Holdings Llc Stable water in oil aminophylline emulsions
JP2005508953A (ja) 2001-10-10 2005-04-07 スージェン・インコーポレーテッド キナーゼ阻害剤としての３−［４−（置換ヘテロサイクリル）−ピロール−２−イルメチリデン］−２−インドリノン誘導体
JP4563679B2 (ja) * 2001-12-06 2010-10-13 デューク ユニバーシティ 形成外科における組織弁壊死の予防
WO2003075851A2 (en) * 2002-03-06 2003-09-18 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
WO2003088961A1 (en) 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US20040147534A1 (en) * 2003-01-23 2004-07-29 Foote Mary Ann Topical composition and method for treating occlusive wounds
US6863825B2 (en) 2003-01-29 2005-03-08 Union Oil Company Of California Process for removing arsenic from aqueous streams
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
US20060147504A1 (en) * 2004-12-30 2006-07-06 Bobby Corry Feminine anti-itch cloth
US8252308B2 (en) * 2005-01-27 2012-08-28 C.B. Fleet Company Inc. Feminine anti-itch gel
WO2006084913A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Device for treatment of rectal disorders, and manufacturing process for the same, involving nitric oxide
AU2006334020B2 (en) 2005-12-30 2012-07-05 Mor Research Applications Ltd. Device and method for treating the anal sphincter
WO2007081521A2 (en) * 2006-01-05 2007-07-19 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
NZ575652A (en) * 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
KR20090083479A (ko) * 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
US8066874B2 (en) 2006-12-28 2011-11-29 Molycorp Minerals, Llc Apparatus for treating a flow of an aqueous solution containing arsenic
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US8349764B2 (en) 2007-10-31 2013-01-08 Molycorp Minerals, Llc Composition for treating a fluid
US8252087B2 (en) 2007-10-31 2012-08-28 Molycorp Minerals, Llc Process and apparatus for treating a gas containing a contaminant
WO2010146591A2 (en) 2009-06-18 2010-12-23 Rdd Pharma Ltd. Methods and devices for delivery of pharmaceutical agents within orifices of the body
US8778969B2 (en) * 2009-11-07 2014-07-15 Peter H Proctor Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines
DK2512479T3 (en) * 2009-12-18 2016-06-06 Exodos Life Sciences Ltd Partnership Compositions for the treatment of peripheral vascular disease
CN102145004B (zh) * 2010-02-09 2012-03-21 鲁南制药集团股份有限公司 己酮可可碱在制备预防或治疗功能性便秘的药物中的用途
EP2558101A4 (en) * 2010-04-15 2013-09-18 Univ Mcgill TOPICAL TREATMENTS OF PAIN
US9233863B2 (en) 2011-04-13 2016-01-12 Molycorp Minerals, Llc Rare earth removal of hydrated and hydroxyl species
US9743857B2 (en) 2011-12-16 2017-08-29 The Regents Of The University Of California Digital manometry finger-mountable sensor device
CN103393690B (zh) * 2013-08-01 2016-05-11 南通大学附属医院 Katp通道开放剂在制备治疗术后疼痛药物中的应用
WO2015112588A1 (en) 2014-01-22 2015-07-30 Biomimetix Jv, Llc Methods of treating skin disorders
WO2015112586A1 (en) * 2014-01-22 2015-07-30 Duke University Methods of treating pruritus
MX370462B (es) 2014-03-07 2019-12-13 Secure Natural Resources Llc Oxido de cerio (iv) con propiedades de remocion de arsenico excepcionales.
RU2595799C1 (ru) * 2015-05-14 2016-08-27 Светлана Николаевна Суслина Композиция для лечения анальных трещин в форме крема
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
EP3801460B1 (en) * 2018-06-01 2025-03-12 Tavanta Therapeutics Hungary Incorporated Topical amlodipine salts for the treatment of anorectal diseases
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (en) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methods of treating depressive disorders
TW202245744A (zh) 2021-02-09 2022-12-01 加拿大商再諾製藥公司 治療失樂症之方法及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
GB9119467D0 (en) * 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
ZA941027B (en) * 1993-02-16 1994-11-11 Smithkline Beecham Corp Chemical compounds
WO1994022460A1 (en) * 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
US5948762A (en) * 1993-07-16 1999-09-07 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor
WO1995006466A1 (en) * 1993-09-01 1995-03-09 Koren Laboratories Pty. Limited Treatment of anorectal disorders
PT719145E (pt) * 1994-05-27 2001-01-31 Cellegy Pharma Inc Composicao dadora de oxido nitrico para tratamento de desordens anais
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
CA2270118A1 (en) * 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
DE69735552T3 (de) * 1996-12-23 2009-08-13 S.L.A. Pharma Ag Pharmazeutische zubereitung zur behandlung der analinkontinenz und analem juckreiz
CN1298309A (zh) * 1998-02-27 2001-06-06 同步神经元有限责任公司 治疗肛门区疼痛的方法及其组合物
ES2205945T3 (es) * 1998-10-23 2004-05-01 Pfizer Inc. Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de disfunciones sexuales.

Also Published As

Publication number Publication date
PL348817A1 (en) 2002-06-17
CN1149983C (zh) 2004-05-19
WO2000035434A3 (en) 2000-11-30
US6395736B1 (en) 2002-05-28
NO20012916D0 (no) 2001-06-13
JP2002542147A (ja) 2002-12-10
US20010012856A1 (en) 2001-08-09
CA2354543A1 (en) 2000-06-22
CZ20012113A3 (cs) 2001-11-14
HUP0104676A2 (en) 2002-06-29
AU2176300A (en) 2000-07-03
AU764921B2 (en) 2003-09-04
CN1526448A (zh) 2004-09-08
KR20010093828A (ko) 2001-10-29
EP1143956A2 (en) 2001-10-17
HUP0104676A3 (en) 2005-12-28
WO2000035434A2 (en) 2000-06-22
EP1143956A3 (en) 2001-12-12
IL143726A0 (en) 2002-04-21
BR9916162A (pt) 2001-09-04
CN1330539A (zh) 2002-01-09

Similar Documents

Publication Publication Date Title
NO20012916D0 (no) Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser
NO20003096D0 (no) Sammensetninger og fremgangsmÕter for behandling av ADD
DK1109453T3 (da) Sammensætninger og fremgangsmåder til behandling af mitokondrielle sygdomme
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
DK0971735T3 (da) Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom
DK1123313T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
NO20005017D0 (no) Metoder og viskøse sammensetninger for behandling av brønner
DE69926493D1 (de) Kühleinrichtung und kühlverfahren
NO982265D0 (no) Diagnostikk for og mediatoter for inflammatoriske forstyrrelser
NO20004896D0 (no) Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
ZA991053B (en) Method and composition for treatment of inflammatory conditions.
NO985385L (no) Bitumensammensetninger og fremgangsmÕte for fremstilling derav
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
HK2101920A1 (zh) 抑制血管生成的模型和方法
DE69924489D1 (de) Getreide-beta-glukanzusammensetzungen und verfahren
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
EP1073333A4 (en) S-RABEPRAZOLE COMPOSITIONS AND METHODS
DE69932573D1 (de) Wiedergabeverfahren und Wiedergabegerät
ATE209195T1 (de) Naphthylverbindungen und zusammensetzungen
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
NO20022057L (no) Fremgangsmåte og sammensetning for å behandle lungesykdommer
DE69918625D1 (de) Wiedergabegerät und Wiedergabeverfahren
PT1051172E (pt) Metodo para tratamento da dpco

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application